GlassScriptPhysician profile
Arul P Kannan
NPI 1023008984
$10,311.45
in general payments reported to CMS, 2019-2025
38 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,996 · 2020: $1,464 · 2021: $2,021 · 2022: $1,548 · 2023: $1,087 · 2024: $1,291 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,489.11 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $927.79 | 2021-2025 | |
| Novo Nordisk INC | $763.94 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $738.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $716.68 | 2021-2024 | |
| Pfizer INC. | $683.73 | 2019-2023 | |
| Allergan, INC. | $620.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.68 | 2019-2022 | |
| Lilly USA, LLC | $483.07 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $233.38 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $179.75 | 2021-2024 | |
| Amarin Pharma, INC. | $175.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $166.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.49 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $153.57 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arul Kannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.